AC
VKTX icon

Ascend Capital’s Viking Therapeutics VKTX Stock Holding History

Ascend Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-488,208
Closed -$932K – 249
2017
Q3 		$932K Buy
+488,208
New +$554K 0.04% 153

Other funds holding VKTX

SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return
EGI
EAM Global Investors Solana Beach, California $34.8M AUM 275.91% 1-Year Est. Return

Ascend Capital's VKTX Position: Q4 2017 in Review

Ascend Capital sold out of Viking Therapeutics (VKTX) in Q4 2017, closing a stake of 488,208 shares — an estimated $932K sold.

Ascend Capital first reported a position in VKTX in Q3 2017 and held it in 1 quarter. The position peaked at $932K in Q3 2017. 33 funds tracked by Wall St. Rank hold VKTX as of Q4 2017.

  • Ascend Capital reported no remaining Viking Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Ascend Capital sold 488,208 Viking Therapeutics shares in Q4 2017, an estimated $932K.
  • Ascend Capital first reported a position in Viking Therapeutics in Q3 2017 and held it in 1 quarter.
  • Ascend Capital's Viking Therapeutics position peaked at $932K in Q3 2017.
  • 33 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2017.

Based on Ascend Capital's 13F filing for Q4 2017, filed 13 Feb 2018.